ShareValue scores for AARTIPHARM.NSE: Valuation 53, Quality 54, Growth 19, Health 47.

AARTIPHARM.NSE
NSE

Aarti Pharmalabs Limited

₹692.25(+1.35%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 15%
Valuation
53
Fair Value
Price vs Value
Quality
54
Moderate
Business Strength
Growth
19
Weak
Revenue & Earnings
Health
47
Moderate
Financial Stability
Momentum
61
Bullish
Price Trend

Company Details

About

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026